Population Pharmacokinetic Model of Methotrexate in Brazilian Pediatric Patients with Acute Lymphoblastic Leukemia

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2023 Jun 8

PMID 37291462

Authors

Pricilla de Oliveira Henz

Amanda Valle Pinhatti

Lauro Jose Gregianin

Manoela Martins

Marina Curra

Bibiana Verlindo de Araujo

Teresa Dalla Costa

Affiliations

Soon will be listed here.

Abstract

Objectives: Methotrexate (MTX) is subject to therapeutic drug monitoring because of its high pharmacokinetic variability and safety risk outside the therapeutic window. This study aimed to develop a population pharmacokinetic model (popPK) of MTX for Brazilian pediatric acute lymphoblastic leukemia (ALL) patients who attended the Hospital de Clínicas de Porto Alegre, Brazil.

Methods: The model was developed using NONMEM 7.4 (Icon®), ADVAN3 TRANS4, and FOCE-I. To explain inter-individual variability, we evaluated covariates from demographic, biochemical, and genetic data (single nucleotide polymorphisms [SNPs] related to the transport and metabolism of drugs).

Results: A two-compartment model was built using 483 data points from 45 patients (0.33-17.83 years of age) treated with MTX (0.25-5 g/m) in different cycles. Serum creatinine (SCR), height (HT), blood urea nitrogen (BUN) and a low BMI stratification (according to the z-score defined by the World Health Organization [LowBMI]) were added as clearance covariates. The final model described MTX clearance as [Formula: see text]. In the two-compartment structural model, the central and peripheral compartment volumes were 26.8 L and 8.47 L, respectively, and the inter-compartmental clearance was 0.218 L/h. External validation of the model was performed through a visual predictive test and metrics using data from 15 other pediatric ALL patients.

Conclusion: The first popPK model of MTX was developed for Brazilian pediatric ALL patients, which showed that inter-individual variability was explained by renal function and factors related to body size.

Citing Articles

Anticipating Leucovorin Rescue Therapy in Patients with Osteosarcoma through Methotrexate Population Pharmacokinetic Model.

Olivo L, de Oliveira Henz P, Wermann S, Dias B, Porto G, Pinhatti A Pharmaceutics. 2024; 16(9).

PMID: 39339216 PMC: 11434990. DOI: 10.3390/pharmaceutics16091180.

Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients.

Rahmayanti S, Amalia R, Rusdiana T Cancer Chemother Pharmacol. 2024; 94(2):141-155.

PMID: 39002021 DOI: 10.1007/s00280-024-04694-0.

References

Dores G, Devesa S, Curtis R, Linet M, Morton L . Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2011; 119(1):34-43. PMC: 3251235. DOI: 10.1182/blood-2011-04-347872. View

Chibber S, Hassan I, Farhan M, Naseem I . In vitro pro-oxidant action of Methotrexate in presence of white light. J Photochem Photobiol B. 2011; 104(3):387-93. DOI: 10.1016/j.jphotobiol.2011.04.005. View

Bleyer W . The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978; 41(1):36-51. DOI: 10.1002/1097-0142(197801)41:1<36::aid-cncr2820410108>3.0.co;2-i. View

Maloney K, Devidas M, Wang C, Mattano L, Friedmann A, Buckley P . Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. J Clin Oncol. 2019; 38(6):602-612. PMC: 7030893. DOI: 10.1200/JCO.19.01086. View

Aumente D, Santos Buelga D, Lukas J, Gomez P, Torres A, Garcia M . Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006; 45(12):1227-38. DOI: 10.2165/00003088-200645120-00007. View

Beechinor R, Thompson P, Hwang M, Vargo R, Bomgaars L, Gerhart J . The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group. Clin Pharmacokinet. 2019; 58(7):899-910. PMC: 6658326. DOI: 10.1007/s40262-018-00734-0. View

Buitenkamp T, Mathot R, de Haas V, Pieters R, Zwaan C . Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica. 2010; 95(7):1106-13. PMC: 2895034. DOI: 10.3324/haematol.2009.019778. View

Hui K, Chu H, Fong P, Cheng W, Lam T . Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma. J Clin Pharmacol. 2018; 59(4):566-577. DOI: 10.1002/jcph.1349. View

Medellin-Garibay S, Hernandez-Villa N, Correa-Gonzalez L, Morales-Barragan M, Valero-Rivera K, Resendiz-Galvan J . Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019; 85(1):21-31. DOI: 10.1007/s00280-019-03977-1. View

10.

Odoul F, Le Guellec C, Lamagnere J, Breilh D, Saux M, Paintaud G . Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fundam Clin Pharmacol. 1999; 13(5):595-604. DOI: 10.1111/j.1472-8206.1999.tb00366.x. View

11.

Schulte R, Choi L, Utreja N, Van Driest S, Stein C, Ho R . Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma. Clin Transl Sci. 2020; 14(1):343-353. PMC: 7877862. DOI: 10.1111/cts.12879. View

12.

Anderson B, Allegaert K, Holford N . Population clinical pharmacology of children: general principles. Eur J Pediatr. 2006; 165(11):741-6. DOI: 10.1007/s00431-006-0188-y. View

13.

De Mattia E, Toffoli G . C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer. 2009; 45(8):1333-51. DOI: 10.1016/j.ejca.2008.12.004. View

14.

Lui G, Treluyer J, Fresneau B, Piperno-Neumann S, Gaspar N, Corradini N . A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. J Clin Pharmacol. 2018; 58(12):1541-1549. DOI: 10.1002/jcph.1252. View

15.

Kim I, Yun H, Choi B, Han N, Park S, Lee E . ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis. Clin Ther. 2012; 34(8):1816-26. DOI: 10.1016/j.clinthera.2012.06.022. View

16.

Frenia M, Long K . Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother. 1992; 26(2):234-7. DOI: 10.1177/106002809202600219. View

17.

Inose R, Hashimoto N, Hosomi K, Yokoyama S, Takada M . Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis . Int J Clin Pharmacol Ther. 2019; 58(3):131-138. DOI: 10.5414/CP203604. View

18.

Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J . Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000; 34(9):1024-7. DOI: 10.1345/aph.19094. View

19.

Kitaoka S, Terasawa M, Goto E, Miyaji T, Tsuchiya S, Konno T . Trimethoprim interference in methotrexate assay by an enzyme inhibition assay kit. Tohoku J Exp Med. 1986; 150(4):481-2. DOI: 10.1620/tjem.150.481. View

20.

Csordas K, Lautner-Csorba O, Semsei A, Harnos A, Hegyi M, Erdelyi D . Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2014; 166(3):410-20. DOI: 10.1111/bjh.12886. View